Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-03-27

Clinical Trial Update: Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation [Phase 4]

View source ↗

Summary

Phase 4 trial assessing temporal dependency of myocardial blood flow measurements using regadenoson and Rubidium-82 PET.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lexiscan (regadenoson)

Snippet

Sponsor: Timothy M. Bateman, MD | Conditions: Myocardial Blood Flow Reserve | Phase 4 | Status: COMPLETED | Results posted: 2017-03-27